Author Affiliations: University of Texas MD Anderson Cancer Center, Houston (email@example.com).
To the Editor: Dr Neoptolemos and colleagues1 reported results from the large, multicenter European Study Group for Pancreatic Cancer (ESPAC)-3 periampullary randomized controlled trial, which demonstrated no significant overall survival benefit from adjuvant chemotherapy in patients with nonpancreatic periampullary adenocarcinoma. We have 2 comments with regard to the trial data.
Overman M, Wang H, Varadhachary GR. Adjuvant Chemotherapy for Resected Periampullary Adenocarcinoma. JAMA. 2012;308(18):1855-1856. doi:10.1001/jama.2012.13952